The invention relates to application of epigallocatechin gallate (EGCG) combined with a tyrosine kinase inhibitor in the preparation of a cancer treatment medicament, and belongs to the technical field of biological medicines. The invention provides a drug administration method combining epigallocatechin gallate (EGCG) as a lead compound with a tyrosine kinase inhibitor, and the combined use can obviously inhibit the growth of EGFR wild-type tumors, and reduce the treatment risk and toxic or side effects caused by anti-cancer drugs in larger doses. The invention improves the sensitivity of theinhibitor and widens the application range of the inhibitor. The invention provides an effective treatment strategy for EGFR wild-type cancer patients.